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circulating RAGE ligands is necessary to 
establish a reliable tool for the assessment 
of the activity of the RAGE system in human 
subjects. Th e study may also be relevant to 
the role of RAGE and its circulating ligands 
in other diseases with an activated AGE –
 RAGE axis, such as carcinomas, Alzhei mer ’ s 
disease, and atherosclerosis. Th ese aggregates 
may be general phenomena, and the investi-
gation of plasma from patients suffering 
from these diseases may help to clarify the 
role of the endo genous ligands. 
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 Maximal  ‘ CD80-uria ’ with 
minimal change 
 Andreas D.  Kistler 1 and  Jochen  Reiser 1 
 Differentiation between minimal-change disease and focal segmental 
glomerulosclerosis remains challenging, particularly at early stages in 
children and adults. Garin  et al. identify urinary CD80 excretion levels as a 
potential marker to differentiate the former entity from the latter. Thus, 
CD80 expression on podocytes, which was initially described in mouse 
models of foot process effacement and human lupus nephritis, is now 
brought toward clinical application for use as a diagnostic biomarker. 
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syndrome. Th e disease is ultrastructurally 
characterized by podocyte foot process 
effacement without light-microscopic 
signs of glomerulosclerosis and interstitial 
fibrosis. Some patients who on initial 
evaluation are diagnosed as having MCD 
later develop focal segmental glomerulo-
sclerosis (FSGS), a process of progressive 
glomerular scarring. It is an ongoing 
debate whether MCD and FSGS represent 
diff erent stages of one common patho-
physiological process or whether they are 
diff erent disease entities, with some FSGS 
patients initially misdiagnosed as having 
MCD because of biopsy sampling error. 
 Garin  et al. 1 (this issue) now demon-
strate that urine levels of CD80 may be 
used to distinguish MCD from FSGS. 
Th ey have previously shown signifi cantly 
elevated urinary CD80 levels in pediatric 
patients with MCD during relapse as com-
pared with MCD in remission, healthy 
controls, and a small number of patients 
with other glomerular diseases. 2 They 
now extend their previous studies by com-
paring MCD patients with a group of 
22 FSGS patients. Th ey were able to show 
that the elevated urinary CD80 levels are 
specifi c to MCD as compared with FSGS 
patients with similar degrees of proteinu-
ria. Urinary CD80 levels had a high dis-
criminatory value for the two entities, with 
an area under the receiver operating char-
acteristic curve of 0.99. These findings 
were corroborated with immunofl uores-
cent stainings of biopsy samples showing 
high expression of CD80 in glomeruli of 
MCD patients in relapse but not of MCD 
patients in remission or of FSGS patients. 
 CD80 — also termed B7-1 — is a trans-
membrane protein expressed on the sur-
face of B cells and other antigen-presenting 
cells, where it serves as a costimulatory 
signal for T cells through binding to its 
receptors CD28 and CTLA-4. Beyond its 
function as a costimulatory molecule, a 
novel role for CD80 expressed on podo-
cytes was recently found. 3 CD80 is upreg-
ulated in at least two genetic mouse 
models of glomerular disease, the integrin 
  3   −  /  −   and the nephrin   −  /  −   mouse. In 
wild-type mice, podocyte expression of 
CD80 can be induced by the endotoxin 
lipopolysaccharide (LPS) through toll-
like receptor 4 (TLR-4) activation. LPS 
injection leads to transient podocyte foot 
pro cess effacement and proteinuria 
in mice, an eff ect that is independent of 
lymphocytes, as it also occurs in SCID 
mice that are devoid of lymphocytes. 
CD80-defi cient mice are protected from 
LPS-mediated podocyte injury. Another 
way to induce CD80 expression in podo-
cytes is treatment with the antibiotic 
puromycin aminonucleoside. Thus, 
induction of CD80 is an event common 
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to genetic, immune-mediated, and toxic 
forms of podocyte injury and seems to be 
downstream of various signaling path-
ways. Podocyte expression of CD80 leads 
to sequestration of the essential podocyte 
proteins nephrin, CD2AP, and ZO-1, 
causing disruption of the slit diaphragm 
complex  in vitro . 3 The identification 
of upregulated CD80 in integrin   3   −  /  −  
mice further suggests a possible link to 
integrin signaling. 
 Structurally, the LPS mouse model of 
podocyte injury shares key features with 
MCD in that it exhibits isolated podocyte 
foot process eff acement that is fully rever-
sible. It has therefore been used as an animal 
model for MCD. It is noteworthy that this 
structural similarity is now corroborated 
on the molecular level by the study of Garin 
 et al. , 1 justifying the use of the LPS model 
to identify mechanisms of podocyte injury 
and potential treatment targets for MCD. 
One obvious diff erence, however, is the 
self-limiting nature of the LPS model in 
contrast to the prolonged course of MCD. 
It can be speculated that a physiological 
role of podocyte CD80 induction is to allow 
excretion of pathogens during infections. 4 
In MCD, the onset of nephrotic syndrome 
is oft en preceded by an infection or allergic 
reaction. Th is raises the intriguing possibil-
ity that MCD results from the prolonged 
activation of a normally benefi cial response 
( Figure 1 ). Th e mechanisms that promote 
persistence of CD80 expression in MCD, 
however, remain elusive. 
 How does CD80 enter the urine? And 
does urinary excretion of CD80 have a 
pathophysiological function? In addition 
to its transmembrane form, CD80 exists 
as a smaller soluble circulating molecule, 
which is generated by B cells through 
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 Figure 1  |  The CD80 pathway in the lipopolysaccharide mouse model of proteinuria and its putative physiological and pathophysiological 
roles in humans. In mice, lipopolysaccharide injection leads to toll-like receptor 4 activation, CD80 induction, and consecutive slit diaphragm 
disruption with proteinuria. Proteinuria spontaneously resolves within 72  h of a single lipopolysaccharide injection. In humans, CD80 induction 
in podocytes may be a physiological response to infections and facilitate the excretion of pathogens by transiently increasing the glomerular 
permeability to macromolecules. Modifying genetic or environmental factors may lead to persistence of CD80 induction after a triggering event in 
minimal-change disease (MCD). In lupus nephritis, CD80 induction represents one of several pathophysiological pathways. Podocyte CD80 expression 
is detectable in both MCD and lupus nephritis and correlates with disease severity in the latter. In contrast, urinary excretion of CD80 is found only in 
MCD, not in lupus nephritis. FP, foot process; LPS, lipopolysaccharide; SD, slit diaphragm; TLR-4, toll-like receptor 4. 
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alternative splicing. Th us, Garin  et al. 1 
had to address the question of whether 
urinary CD80 may arise from fi ltration 
of circulating short CD80, as their 
ELISA-based measurements of urinary 
CD80 can not diff erentiate between soluble 
and  transmembrane CD80. Th ey did so by 
providing immunoprecipitation – western 
blot analyses of some urine samples, 
demonstrating that urine contains full-
length CD80. It is therefore unlikely that 
urinary CD80 arises from glomerular 
fi ltration of circulating soluble CD80. By 
immunostaining of biopsy samples, 
Garin  et al. 1 were further able to show 
CD80 expression in relapsing MCD 
glomeruli but not in MCD tubules and 
not in FSGS or MCD in remission. Th ese 
data provide evidence that urinary CD80 
originates from podocytes, although they 
do not defi nitely exclude a tubular origin. 
It is noteworthy that CD80 expression 
has been shown on tubular epithelial 
cells of IgA nephropathy patients, 5 rais-
ing the possibility that urinary CD80 is 
derived from tubular epithelium. Assum-
ing that urinary CD80 stems from podo-
cytes, another open question is by which 
mechanism it ends up in the urine. Uri-
nary CD80 may merely refl ect the pres-
ence of CD80-positive podocytes lost 
into the urine, 6 or it may be contained in 
granular membrane structures that are 
found in the urine during podocyte 
injury. 7 Since slit diaphragm proteins 
have been found to be shed into the 
urine 8,9 and CD80 binds and sequesters 
slit diaphragm proteins, 3 CD80 may fol-
low slit diaphragm proteins that are shed 
into the urine. Alternatively, CD80 may 
be actively shed from podocytes as a pro-
tective mechanism. In this context it is of 
interest that urinary CD80 levels are not 
signifi cantly increased in patients with 
lupus, 2 another disease in which induc-
tion of CD80 has been demonstrated in 
podocytes. 3 One might speculate that 
active shedding of CD80 protects podo-
cytes from progressive damage in MCD 
whereas, in severe forms of lupus nephri-
tis, accumulation of CD80 leads to 
 progressive and destructive changes. 
A more detailed analysis of patient 
urines, including diff erential ultracen-
trifugation to isolate cellular and subcel-
lular urinary contents followed by 
immunofl uorescent and immunoelec-
tron microscopic analysis, would be a 
fi rst step to clarify the mechanisms of 
CD80 excretion. 
 Irrespective of these unanswered patho-
physiological questions, urinary CD80 is 
a promising diagnostic bio marker for 
MCD. Before getting to clinical use, how-
ever, validation in an independent patient 
cohort is needed, preferably in a multi-
centric approach. In the study by Garin 
 et al. in this issue, 1 the MCD and FSGS 
patient groups signifi cantly diff ered in 
terms of age (mean 6 versus 36 years) and 
sex (60 versus 18 % male); therefore, con-
fi rmation in age- and sex-matched patient 
groups would be desirable. Furthermore, 
control populations with diff erent kinds 
of glomerular diseases would be useful 
to prove the specifi city of  ‘ CD80-uria ’ for 
MCD. Another important question 
regarding diagnostic utility is whether 
patients who are initially classified 
as having MCD, but later develop 
FSGS, display low urinary CD80 levels 
on initial presentation and could thus be 
identifi ed earlier. Despite these limita-
tions, the study by Garin  et al. 1 puts us a 
significant step forward as our quest 
for glomerular kidney disease markers 
is ongoing. 
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